Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xofigo in NSCLC with Bone Metastases
NCT02283749Phase 2Completed
- Sponsor
- Angela Taber
- Start
- Sep 2015
- Primary completion
- Jul 2018
- Modality
- Radiopharmaceutical
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of radium-223 dichloride in non-small cell lung cancer (NSCLC), sponsored by Angela Taber. Primary endpoint: Number of Symptomatic Skeletal Events at 1 year. Started Sep 2015; status: completed.
02
Drugs
radium-223 dichloride
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02283749.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02283749.